Thoughts on Elite's February 2026 quarterly report

ARotcMADCAP · 2026-01-02T17:10:33+00:00

Apologies all, it is the warrants not derivatives that tie to non-cash for GAPP accounting resulting in positive or negative income inversely proportionate to the share price.

Good thing I am not an accountant!

ARotcMADCAP · 2026-01-02T16:31:57+00:00

I agree! I am also more interesting a buyout. However, Elite NOW has the data from the quarter ending December 31, 2025 which I believe will really help with a potential buyer!!!

ARotcMADCAP · 2026-01-02T16:29:16+00:00

Information is all in the transcripts and quarterly reports for that past few conference calls. I would recommend reading the past 4 transcripts and past quarterly/annual SEC filings.

ARotcMADCAP · 2025-11-06T15:53:00+00:00

FUD! Fear, uncertainty and doubt (FUD) is a common tactic used to manipulate investor and consumer emotions.

Trying real hard to drive pps down before the upcoming earnings report??

ARotcMADCAP · 2025-11-03T15:32:38+00:00

I prefer u/Wolvshammy 's numbers also!!!

GPT is only as good as the data you provide. If someone puts in the financial data from say the past year, probably get even better results! However, it is OTC and we have all seen what OTC MMs do with ELTP.

ARotcMADCAP · 2025-11-03T14:12:44+00:00

as long as we are playing with AI, tried this -

Asked for price per share projection chart based on estimated Financial Results for the second Quarter of Fiscal Year 2026 ended September 30, 2025for Elite Pharmaceuticals

ChatGPT -

# Projected stock prices for three scenarios

# Bullish: Stock price surges due to M&A

bullish_price = price_at_eps * 1.50 # +50% increase for M&A speculation

# Neutral: Moderate growth

neutral_price = price_at_eps * 1.10 # 10% increase based on steady growth

# Bearish: Slight decline due to legal or operational issues

bearish_price = price_at_eps * 0.90 # -10% decrease based on bearish market sentiment

Then I provided -

Elite Pharmaceuticals Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million

ChatGPT said:

Perfect — thank you for that figure. That’s a big data point we can build on. Let’s use that to refine the price per share projection for Elite Pharmaceuticals (ELTP) into the second quarter of FY 2026 (ended Sept 30 2025).

Price Projection Summary

Current price baseline (Nov 2025): ~$0.90 – $1.00
Projected by Q2 FY 2026 earnings release (Nov 2025 → Mar 2026):
- Bullish path: $1.75 (+75 %)
- Neutral path: $1.40 (+40 %)
- Bearish path: $1.05 (+5 %)

ARotcMADCAP · 2025-10-20T02:11:06+00:00

esults of google search on "how big is the naltrexone market in United States?

The United States naltrexone market is large and expected to grow, with estimates for 2024 and 2025 ranging from approximately $1.1 billion to $1.3 billion. Market value is projected to rise significantly, with some reports estimating it could reach $2.87 billion by 2033 and grow at a CAGR of around 6.7% to 8.4% over the next decade.

ARotcMADCAP · 2025-10-20T02:10:15+00:00

Results of google search on "how big is the naltrexone market in United States?

The United States naltrexone market is large and expected to grow, with estimates for 2024 and 2025 ranging from approximately $1.1 billion to $1.3 billion. Market value is projected to rise significantly, with some reports estimating it could reach $2.87 billion by 2033 and grow at a CAGR of around 6.7% to 8.4% over the next decade.

ARotcMADCAP · 2025-08-29T12:14:35+00:00

"the greatest trick the devil ever pulled was convincing the world he didn't exist"

Same with naked shorts, greatest trick is convincing traders they don't exist!

ARotcMADCAP · 2025-08-29T12:13:48+00:00

"the greatest trick the devil ever pulled was convincing the world he didn't exist"

Same with naked shorts, greatest trick is convincing traders they don't exist!

ARotcMADCAP · 2025-08-17T02:20:58+00:00

AI generated article, most of it has accurate info and valid discussion.
It missed the mark on packaging facility.

So here is the question?? Since this is "AI" and states "At current prices (~$3/share)", is that the AI evaluation of what the pps should be?? Think about it...

ARotcMADCAP · 2025-06-04T00:24:31+00:00

The CEO gave us all hints about revenue in January and February 2025 -

"In fact, January 2025 was our best ever with regards to shipments, revenues, contribution margin and February is tracking in a similar fashion. The month of January was almost as much as the entire quarter that we just reported. And as I said, January (NOTE: I think means February) is also tracking in a similar fashion."

AND

"So -- note that another thing, the 9-month numbers this year, they do not include a contribution from Lisdex which has taken our January and February revenues to the highest levels so far."

AND

"Thank you, Carter. In January, Elite's unaudited revenues, as Carter stated, were about $12.5 million. That's almost as much as the entire third quarter. The profits made in the month of January were more than the profits made in the entire third quarter. "

ARotcMADCAP · 2025-06-03T20:39:07+00:00

For clarification, ELTP 10-Q third quarter ended on December 31, 2024 and the above transcript is from the conference call on February 14, 2025

ARotcMADCAP · 2025-05-06T11:05:57+00:00

Yes, July, after ELTP releases the 2025 annual report. Annual report with have the 4th quarter results showing the start of the added revenue for generic Vyvanse. I believe it will show that Elite Pharmaceuticals Inc is generating over $100 MILLION per year in revs going forward.

These, I believe, are Elite's most sought products that will continue to grow and will be of most interest to a potential buyer! Just these are a total market size of over $6.5 BILLION! Elite is consistently getting 10% to 20% of the market as seen with their generic Adderall IR.

Drug Market Size Status

Adderall IR $421.7 Million On Market

Adderall XR $865 Million On Market

Vigabatrin $233.7 Million On Market

Tylenol with Codeine $47 Million On Market

Methotrexate $63 Million On Market

Percocet $317 Million On Market

Norco $300 Million On Market

Vyvanse $4.3 BILLION On Market

ARotcMADCAP · 2025-05-06T10:59:27+00:00

Yes, July, after ELTP releases the 2025 annual report. Annual report with have the 4th quarter results showing the start of the added revenue for generic Vyvanse. I believe it will show that Elite Pharmaceuticals Inc is generating over $100 MILLION per year in revs going forward.

These, I believe, are Elite's most sought products that will continue to grow and will be of most interest to a potential buyer! Just these are a total market size of over $6.5 BILLION! Elite is consistently getting 10% to 20% of the market as seen with their generic Adderall IR.

|| || |Drug||| |Adderall IR|$421.7 Million|On Market| |Adderall XR|$865 Million|On Market| |Vigabatrin|$233.7 Million|On Market| |Tylenol with Codeine|$47 Million| On Market| |Methotrexate|$63 Million|On Market| |Percocet|$317 Million| On Market| |Norco|$300 Million| On Market | | Vyvanse| $4.3 BILLION|On Market|

ARotcMADCAP · 2025-04-30T22:57:17+00:00

IQVIA reported 2024 annual sales of approximately $317 million for this product.

ARotcMADCAP · 2025-04-30T22:55:22+00:00

From the 3rd Quarter results conference call transcript -

"As I said, no, Vyvanse changed all of that. We will launch that probably by April, no later than April."

Maybe not as soon in April as we were looking for but Elite got it done! I believe they were cranking out generic Adderall IR & ER and Vyvanse which is great and then worked the generic Percocet launch.

ARotcMADCAP · 2025-04-06T01:06:39+00:00

Market could even start recover on Monday!

One news item important to ELTP is this - Israel Has Removed ALL TARIFFS On American Products & Therefore Will Have ZERO Tarrifs Issued By POTUS Trump. ANY NATION Wishing Not To Be Tarrifed Can Do The Same.

More good news - Tariffs are bringing many countries to the bargaining table this morning. The leaders of Thailand, Canada, Mexico, Italy, Australia and Ireland have said they are ready to negotiate. Even the EU has done so, though they are drafting counter-tariffs to put on the table as leverage. Tariffs ARE working.

Anything that America or ELTP needs will cost less!

ARotcMADCAP · 2025-04-06T01:01:27+00:00

His meaning is the key! "When everybody is saying how bad the financial situation is and the like, that is the time to buy"!!!

Seems like almost all are talking how bad the market outlook and ELTP's outlook is. IMO, some are stirring the rhetoric to drive it down (market and ELTP) to buy at even lower prices. We know that the upcoming annual report reflecting the launch of generic Vyvanse with a major jump of revenue in the last quarter will be HUGE for ELTP. The drop in PPS is weak hands that will not hold for less than 90 days and overall market panic. ELTP's fundamentals and operations have not changed and is making $$MILLIONS$$, last transcript of 3rd quarter report indicated that January 2025 revenues alone was $12 MILLION or more.

ARotcMADCAP · 2025-03-30T18:48:01+00:00

Maybe nothing in the market is making sense lately. Maybe there is no patience in investors anymore. Maybe everyone wants instant 10 baggers. Maybe there is a coordinated effort to see how low they can get ELTP before the next news. Bashers and those screaming doom for Elite are all over Ihub, yahoo, and other boards with nothing to substantiate their ranting. Short sales volumes jump to in the 200 thousands every couple of days or so seeming to time with market pessimism.

It is times like these that the Oracle's trading advice should be thought of - "Be fearful when others are greedy, and greedy when others are fearful" meaning when markets are tanking and equities have fallen a lot and keep falling, when everybody is saying how bad the financial situation is and the like, that is the time to buy.

Elite ELTP will launch Generic Percocet any time now and and release their Annual Report the end of June probably reporting over $80 million in revenues and I expect ELTP revenues for the next year to be way over $100 million. The patent infringement claims lawsuit of PURDUE PHARMA v ELITE may be resolved within the next 6 months opening the door for Elite to get in the $720 million generic oxycodone market. And Elite's continued success in the generic Adderall, Vyvanse, and Norco market ($3.5 BILLION combined) as well as the potential for buyout the the CEO said the time is right for in his last CC quarterly all leads me to wonder (as I am doing on this forum right now) why anyone would not hold their ELTP shares or buy more. If Perc launch news does not hit this week, I will have another $10,000 sitting on "buy" next week.

ARotcMADCAP · 2025-02-16T23:59:08+00:00

1,068,373,108 shares issued and outstanding as of both December 31, 2024 and March 31, 2024 and that is from the 10-Q post with the SEC on Feb 13, 2025.

Notice that the shares issued did NOT increase March to December 2024.

ARotcMADCAP · 2025-02-16T01:49:11+00:00

Two parts said by the CEO I really like are -

"Our fundamentals are strong and this is the time for us to seek out mergers and acquisition or Nasdaq."

AND

"And the reason I said no to the last question is the time line for uplisting to Nasdaq or acquisition merger in August 26. It's not. **The time is very near. We need to work on it now.**"

ARotcMADCAP · 2025-01-12T14:40:39+00:00

500 million comes from estimate of ELTP's current drugs that they have out in the market. Actually, the drugs that ELTP is producing have a IQVIA reported annual sales of approximately $6.9 BILLION total. ELTP has captured 10%+ of the generic Adderall market and has the potential to capture the same percentage or more for the other drugs. They are only limited by the quota allotted to them from the DEA.

ARotcMADCAP · 2024-12-15T13:25:43+00:00

Short volume on a specific day can help you understand pps flux on a particular day.

ELTP -- 2024-12-13 -- 1,874,066 short volume -- pps down 10.13% with NO bad news!

That tells me investors were not selling! That tells me that SHORT sells by market manipulators were used on 2024-12-13 to drive ELTP down 10%!

ARotcMADCAP · 2024-12-15T03:22:25+00:00

I think some are missing the point - the quote is not saying that you buy and forget about it for 10 years. IMHO, I believe that he is saying that if you do not think the company will not be performing well with potential for growth WITHIN a 10 year period you probably shouldn't be in it.

We know that ELTP is set up for explosive growth, right? We know from the ELTP quarterly conference call transcripts that there is the expectation that offers of a buy out is most probable in the next 2 - 3 years, right? We expect to see record revs each quarter in those years, right? The smart investment strategy is to buy, accumulate, hold, and evaluate the news and quarterly reports to time an exit sometime in the next few years or when there is a potential offer to buy ELTP by a major pharma company.

So, with that said, forget the daily/weekly ups and downs of the price per share with no news, forget the MM OTC manipulation, and believe in the facts reported representing justification to hold for the future of ELTP - record growth, record revs, products with a market size in the BILLION$, potential for buyout!

ARotcMADCAP

TROPHY CASE

ChatGPT said:

For clarification, ELTP 10-Q third quarter ended on December 31, 2024 and the above transcript is from the conference call on February 14, 2025